STOCK TITAN

Collplant Biotechnologies Ltd - CLGN STOCK NEWS

Welcome to our dedicated page for Collplant Biotechnologies news (Ticker: CLGN), a resource for investors and traders seeking the latest updates and insights on Collplant Biotechnologies stock.

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) pioneers regenerative medicine solutions through its plant-based recombinant human collagen (rhCollagen) technology. This dedicated news hub provides investors and stakeholders with timely updates on clinical advancements, strategic partnerships, and product developments in 3D bioprinting, medical aesthetics, and tissue repair.

Access official press releases covering regulatory milestones, research breakthroughs, and commercial collaborations with industry leaders like AbbVie and Stratasys. Our curated collection includes updates on Vergenix™ wound care products, rhCollagen BioInk applications, and progress in regenerative breast implant development.

Discover comprehensive coverage of financial results, intellectual property expansions, and manufacturing scale-up initiatives. This resource serves as your primary source for tracking CollPlant's progress in addressing unmet needs across orthobiologics, advanced wound care, and organ manufacturing markets.

Bookmark this page for streamlined access to CLGN's latest developments in biocompatible medical solutions. Check regularly for updates on ESG initiatives, patent filings, and clinical trial outcomes that shape the company's position in the $3B+ regenerative medicine sector.

Rhea-AI Summary
CollPlant Biotechnologies (Nasdaq: CLGN) announced a $10 million milestone payment from partner AbbVie Inc., a $29 million cash runway, and financial results for the third quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.63%
Tags
-
Rhea-AI Summary
CollPlant Biotechnologies (CLGN) to report Q3 2023 financial results on November 29, 2023, followed by a conference call and webcast. Investors can participate in the call using the provided dial-in information or the Call me™ feature. A live webcast will also be available, and questions for management can be submitted in advance via email.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
-
Rhea-AI Summary
CollPlant Biotechnologies has secured a patent from the U.S. Patent and Trademark Office for its photocurable dermal filler product candidate. The patent covers a method of filling tissue space under the epidermis by introducing a polymerizable filler solution and applying external light for in-situ polymerization. This patent strengthens CollPlant's intellectual property in the U.S. market and expands the potential uses for its rhCollagen technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.11%
Tags
none
Rhea-AI Summary
CollPlant Biotechnologies joins UN Global Compact to strengthen commitment to sustainability in regenerative and aesthetics medicine industry
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
none
-
Rhea-AI Summary
CollPlant Biotechnologies to participate in H.C Wainwright Annual Growth Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.66%
Tags
conferences
-
Rhea-AI Summary
CollPlant Biotechnologies received a $10 million milestone payment from AbbVie for achieving a major milestone in Q2. The company also entered into a collaboration with Stratasys for the development of bioprinting solutions. Cash and cash equivalents totaled $22.3 million as of June 30, 2023. Revenues for the first six months of 2023 were $10.6 million with operating income of $5.7 million. CollPlant plans to initiate a second large-animal study for regenerative breast implants by year end.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.87%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.26%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.69%
Tags
Collplant Biotechnologies Ltd

Nasdaq:CLGN

CLGN Rankings

CLGN Stock Data

27.72M
7.65M
10.16%
12.23%
0.04%
Biotechnology
Healthcare
Link
Israel
Rehovot